Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||JQ1 + Silmitasertib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JQ1||JQ-1||BET Inhibitor (Pan) 30||JQ1 is a BET bromodomain inhibitor with greatest specificity towards BRD4, resulting in decreased Myc expression, increased cell death, reduced macrophage immunosuppression, and inhibition of tumor growth (PMID: 24231268, PMID: 31018997, PMID: 30906568, PMID: 32800944).|
|Silmitasertib||CX-4945|CX4945||Silmitasertib (CX-4945) inhibits protein kinase CK2 (CSNK2), potentially resulting in decreased growth of tumor cells, alone and in combination with other agents (PMID: 21159648, PMID: 27758824, PMID: 32615532).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute lymphoblastic leukemia||not applicable||JQ1 + Silmitasertib||Preclinical - Cell culture||Actionable||In a preclinical study, JQ-1 and Silmitasertib (CX-4945) demonstrated synergy in T-cell acute lymphocytic leukemia cell lines in culture, resulting in increased apoptosis, with stronger synergism in cell lines with higher CK2 expression levels (PMID: 27758824).||27758824|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|